FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1983896142> ?p ?o ?g. }

• W1983896142 endingPage "e57777" @default.
• W1983896142 startingPage "e57777" @default.
• W1983896142 abstract "To estimate the lifetime cost utility of two antiretroviral regimens (once-daily atazanavir plus ritonavir [ATV+r] versus twice-daily lopinavir/ritonavir [LPV/r]) in Italian human immunodeficiency virus (HIV)-infected patients naïve to treatment.With this observational retrospective study we collected the clinical data of a cohort of HIV-infected patients receiving first-line treatment with LPV/r or ATV+r.A Markov microsimulation model including direct costs and health outcomes of first- and second-line highly active retroviral therapy was developed from a third-party (Italian National Healthcare Service) payer's perspective. Health and monetary outcomes associated with the long-term use of ATV+r and LPV/r regimens were evaluated on the basis of eight health states, incidence of diarrhoea and hyperbilirubinemia, AIDS events, opportunistic infections, coronary heart disease events and, for the first time in an economic evaluation, chronic kidney disease (CKD) events. In order to account for possible deviations between real-life data and randomised controlled trial results, a second control arm (ATV+r 2) was created with differential transition probabilities taken from the literature.The average survival was 24.061 years for patients receiving LPV/r, 24.081 and 24.084 for those receiving ATV+r 1 and 2 respectively. The mean quality-adjusted life-years (QALYs) were higher for the patients receiving LPV/r than those receiving ATV+r (13.322 vs. 13.060 and 13.261 for ATV+r 1 and 2). The cost-utility values were 15,310.56 for LPV/r, 15,902.99 and 15,524.85 for ATV+r 1 and 2.Using real-life data, the model produced significantly different results compared with other studies. With the innovative addition of an evaluation of CKD events, the model showed a cost-utility value advantage for twice-daily LPV/r over once-daily ATV+r, thus providing evidence for its continued use in the treatment of HIV." @default.
• W1983896142 created "2016-06-24" @default.
• W1983896142 creator A5007187590 @default.
• W1983896142 creator A5014801178 @default.
• W1983896142 creator A5025989390 @default.
• W1983896142 creator A5056828553 @default.
• W1983896142 creator A5068255264 @default.
• W1983896142 creator A5077495376 @default.
• W1983896142 creator A5080933580 @default.
• W1983896142 creator A5081790956 @default.
• W1983896142 creator A5088917154 @default.
• W1983896142 date "2013-02-27" @default.
• W1983896142 modified "2023-10-12" @default.
• W1983896142 title "Cost-Utility Analysis of Lopinavir/Ritonavir versus Atazanavir + Ritonavir Administered as First-Line Therapy for the Treatment of HIV Infection in Italy: From Randomised Trial to Real World" @default.
• W1983896142 cites W1967696534 @default.
• W1983896142 cites W1972388955 @default.
• W1983896142 cites W2004681966 @default.
• W1983896142 cites W2010913334 @default.
• W1983896142 cites W2012216695 @default.
• W1983896142 cites W2018384320 @default.
• W1983896142 cites W2038002163 @default.
• W1983896142 cites W2049969210 @default.
• W1983896142 cites W2056827810 @default.
• W1983896142 cites W2063994782 @default.
• W1983896142 cites W2080341658 @default.
• W1983896142 cites W2092238432 @default.
• W1983896142 cites W2097255151 @default.
• W1983896142 cites W2135857551 @default.
• W1983896142 cites W2139276221 @default.
• W1983896142 cites W2148989961 @default.
• W1983896142 cites W2161795936 @default.
• W1983896142 cites W2167528679 @default.
• W1983896142 cites W2171236519 @default.
• W1983896142 doi "https://doi.org/10.1371/journal.pone.0057777" @default.
• W1983896142 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3880403" @default.
• W1983896142 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23460905" @default.
• W1983896142 hasPublicationYear "2013" @default.
• W1983896142 type Work @default.
• W1983896142 sameAs 1983896142 @default.
• W1983896142 citedByCount "14" @default.
• W1983896142 countsByYear W19838961422013 @default.
• W1983896142 countsByYear W19838961422014 @default.
• W1983896142 countsByYear W19838961422015 @default.
• W1983896142 countsByYear W19838961422016 @default.
• W1983896142 countsByYear W19838961422017 @default.
• W1983896142 countsByYear W19838961422018 @default.
• W1983896142 countsByYear W19838961422019 @default.
• W1983896142 countsByYear W19838961422021 @default.
• W1983896142 crossrefType "journal-article" @default.
• W1983896142 hasAuthorship W1983896142A5007187590 @default.
• W1983896142 hasAuthorship W1983896142A5014801178 @default.
• W1983896142 hasAuthorship W1983896142A5025989390 @default.
• W1983896142 hasAuthorship W1983896142A5056828553 @default.
• W1983896142 hasAuthorship W1983896142A5068255264 @default.
• W1983896142 hasAuthorship W1983896142A5077495376 @default.
• W1983896142 hasAuthorship W1983896142A5080933580 @default.
• W1983896142 hasAuthorship W1983896142A5081790956 @default.
• W1983896142 hasAuthorship W1983896142A5088917154 @default.
• W1983896142 hasBestOaLocation W19838961421 @default.
• W1983896142 hasConcept C104863432 @default.
• W1983896142 hasConcept C112930515 @default.
• W1983896142 hasConcept C126322002 @default.
• W1983896142 hasConcept C142462285 @default.
• W1983896142 hasConcept C159047783 @default.
• W1983896142 hasConcept C194828623 @default.
• W1983896142 hasConcept C2777182164 @default.
• W1983896142 hasConcept C2778414717 @default.
• W1983896142 hasConcept C2779298103 @default.
• W1983896142 hasConcept C2781392899 @default.
• W1983896142 hasConcept C2993143319 @default.
• W1983896142 hasConcept C3013748606 @default.
• W1983896142 hasConcept C3019080777 @default.
• W1983896142 hasConcept C512399662 @default.
• W1983896142 hasConcept C64332521 @default.
• W1983896142 hasConcept C71924100 @default.
• W1983896142 hasConceptScore W1983896142C104863432 @default.
• W1983896142 hasConceptScore W1983896142C112930515 @default.
• W1983896142 hasConceptScore W1983896142C126322002 @default.
• W1983896142 hasConceptScore W1983896142C142462285 @default.
• W1983896142 hasConceptScore W1983896142C159047783 @default.
• W1983896142 hasConceptScore W1983896142C194828623 @default.
• W1983896142 hasConceptScore W1983896142C2777182164 @default.
• W1983896142 hasConceptScore W1983896142C2778414717 @default.
• W1983896142 hasConceptScore W1983896142C2779298103 @default.
• W1983896142 hasConceptScore W1983896142C2781392899 @default.
• W1983896142 hasConceptScore W1983896142C2993143319 @default.
• W1983896142 hasConceptScore W1983896142C3013748606 @default.
• W1983896142 hasConceptScore W1983896142C3019080777 @default.
• W1983896142 hasConceptScore W1983896142C512399662 @default.
• W1983896142 hasConceptScore W1983896142C64332521 @default.
• W1983896142 hasConceptScore W1983896142C71924100 @default.
• W1983896142 hasIssue "2" @default.
• W1983896142 hasLocation W19838961421 @default.
• W1983896142 hasLocation W19838961422 @default.
• W1983896142 hasLocation W19838961423 @default.
• W1983896142 hasLocation W19838961424 @default.
• W1983896142 hasLocation W19838961425 @default.
• W1983896142 hasLocation W19838961426 @default.

• next